KLISYRI (tirbanibulin) is a topical medication approved for the treatment of actinic keratosis on the face or scalp. Actinic keratosis is a condition characterized by rough, scaly patches on the skin, resulting from prolonged exposure to the sun, and can potentially lead to skin cancer if left untreated. KLISYRI works at the cellular level to inhibit the growth of these lesions. It is applied directly to the affected area of the skin as a once-daily treatment for a short duration, typically over five consecutive days. This medication represents a targeted approach to managing actinic keratosis, offering a non-invasive treatment option that can be used in the convenience of a patient's home.